Raphael Pharmaceutical Inc

For the period ended Dec 31, 2023. Filed Mar 28, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 28, 2024

RAPHStored price and day change unavailable

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Item 8. Consolidated Statements of Cash Flows

	Year Ended December 31,
2023 · 2022
Cash flows from operating activities
Net loss		$(1,284)		$(3,358)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based payment in exchange for services		200		2,290
Depreciation		*		-
Changes in:
Other current assets		36		226
Related parties		35		(19)
Other accounts payables and accrued expenses		(190)		102
Net cash used in operating activities		(1,203)		(759)
Cash flows from investing activities
Purchase of fixed assets		-		(2)
Net cash provided by investing activities		-		(2)
Cash flows from financing activities
Receipt of a loan		-		-
Proceeds from issuance of common stock and warrants		1,145		896
Net cash provided by financing activities		1,145		896
Change in cash and cash equivalents		(58)		135
Cash and cash equivalents at the beginning of the year		288		153
Cash and cash equivalents at the end of the year		$230		$288
Non cash supplement
Issuance of shares for past services (Note 6v)		$200	$	-
Issuance of shares for past services	$	-		$150
Non cash issuance costs	$	-		$70
Exercise of warrants (Note 6bb)		$100	$	-

(*)	less than 1 thousand

The accompanying notes are an integral part of the consolidated financial statements.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.